The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Sarcoidosis in the Spotlight: Screening, Treatment & More Insights into Sarcoidosis

Sarcoidosis in the Spotlight: Screening, Treatment & More Insights into Sarcoidosis

June 1, 2021 • By Jason Liebowitz, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Sarcoidosis, sometimes referred to as the great mimicker, presents in myriad ways. At the 2021 ACR State-of-the-Art Clinical Symposium, Marc Judson, MD, chief, Division of Pulmonary and Critical Care Medicine, Albany Medical College, New York, provided an update on the screening and treatment of sarcoidosis in patients. He also discussed drug-induced sarcoidosis-like reaction (DISR), a condition he said should be in the deferential for patients in whom sarcoidosis is suspected.

You Might Also Like
  • 2015 ACR/ARHP Annual Meeting: Unknowns Persist Around Sarcoidosis Etiology, Pathogenesis, Treatment
  • Sarcoidosis: Insights into the Targets of Cellular Immunity
  • 2014 ACR/ARHP Annual Meeting: Diagnosis, Management of Sarcoidosis in the Heart, Central Nervous System
Explore This Issue
June 2021
Also By This Author
  • Ankylosing Spondylitis & Uveitis: An Ophthalmologist’s Perspective

Screening

Dr. Judson noted that the heart, eyes and vitamin D regulation pathway are important places to begin screening for sarcoidosis.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The heart: Among patients with known extra-cardiac sarcoidosis, such symptoms as palpitations lasting more than two weeks, presyncope or syncope, and signs of heart failure should prompt an evaluation for potential cardiac involvement. Objectively abnormal findings may be present on an echocardiogram (e.g., depressed ejection fraction, wall motion abnormalities) or on an electrocardiogram (e.g., first, second- or third-degree atrioventricular nodal block, bundle branch block or supraventricular arrhythmias).

Although proposed screening algorithms differ by organization, Dr. Judson presented evidence that cardiac magnetic resonance imaging (MRI) may be particularly useful. In a study of more than 300 patients with biopsy-proven sarcoidosis, cardiac MRI was found to have higher sensitivity and specificity for the detection of cardiac sarcoidosis than conventional cardiac testing with echocardiogram and electrocardiogram (ECG).1 Detection of cardiac sarcoidosis is of particular importance, because—in contrast to the slow progression of pulmonary fibrosis that can occur in patients with sarcoidosis over months to years—cardiac involvement in sarcoidosis can lead to fatal arrhythmias and sudden cardiac death.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Eyes: With regard to ophthalmic involvement in patients with sarcoidosis, the rationale for screening for sarcoidosis-related eye disease in asymptomatic patients is that this common manifestation of the disease can result in serious consequences even without warning signs.

In a study of 50 patients with biopsy-proven lung sarcoidosis, ocular findings included episcleritis, iris nodules, cataracts, periphlebitis, periarteritis, epiretinal membrane and branch retinal vein occlusion—and more than one in 10 patients lacked ocular symptoms.2 When signs or symptoms do occur, they may include foreign body sensation, blurred vision, floaters or conjunctival hyperemia.

The most serious & permanent damage related to sarcoidosis is from fibrosis. Anti-fibrotic agents may mitigate the effects of fibrotic disease in these patients.

Vitamin D: Vitamin D dysregulation can occur in sarcoidosis. Although calcitriol, the metabolically active form of vitamin D, is normally synthesized entirely in the kidneys, an extra-renal source of calcitriol in sarcoidosis is the alveolar macrophage. These macrophages contain the 1-α hydroxylase enzyme that converts 25(OH) vitamin D to 1,25(OH) vitamin D (i.e., calcitriol). Thus, patients with hypercalcemia can have low 25(OH) vitamin D, low parathyroid hormone and normal to high 1,25(OH) vitamin D.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Meeting Reports Tagged With: ACR State-of-the-Art Clinical Symposium, heart, Sarcoidosis, Vitamin DIssue: June 2021

You Might Also Like:
  • 2015 ACR/ARHP Annual Meeting: Unknowns Persist Around Sarcoidosis Etiology, Pathogenesis, Treatment
  • Sarcoidosis: Insights into the Targets of Cellular Immunity
  • 2014 ACR/ARHP Annual Meeting: Diagnosis, Management of Sarcoidosis in the Heart, Central Nervous System
  • RA Patients May Not Receive Needed Osteoporosis Screening & Treatment

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.